Integrated Wealth Concepts LLC Has $4.91 Million Holdings in Abbott Laboratories $ABT

Key Points

• Integrated Wealth Concepts LLC increased its Abbott Laboratories stake by 40.2% in the second quarter, adding 15,510 shares for a total of 54,074 shares valued at approximately $4.91 million.
• Analysts remain broadly positive on Abbott, with a consensus rating of “Moderate Buy” and an average price target of $119.50; institutional investors own 75.18% of the company.
• Abbott’s latest quarterly results exceeded expectations, reporting $1.31 in EPS and $12.59 billion in revenue, with revenue up 13% year over year. The stock opened at $102.08, down 1.2%.

Integrated Wealth Concepts LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 40.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 54,074 shares of the healthcare product maker's stock after buying an additional 15,510 shares during the period. Integrated Wealth Concepts LLC's holdings in Abbott Laboratories were worth $4,907,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of ABT. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories in the fourth quarter worth approximately $26,000. Institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

ABT has been the subject of several recent research reports. BTIG Research boosted their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a report on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target for the company. Weiss Ratings upgraded shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Trading Down 1.2%

NYSE ABT opened at $102.08 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $105.60 and a 200 day simple moving average of $99.85. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The firm has a market capitalization of $176.63 billion, a P/E ratio of 33.03, a PEG ratio of 1.89 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the prior year, the business posted $1.26 EPS. The business's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.